Literature DB >> 19242370

Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease.

Inge Tinhofer1, Lukas Weiss, Franz Gassner, Gabriele Rubenzer, Claudia Holler, Richard Greil.   

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is a clinically heterogeneous disease in which the clinical course is influenced by the presence or absence of immunoglobulin (Ig) variable heavy chain (VH) gene mutations. The poor clinical outcome of the subgroup with unmutated Ig VH genes has been linked to the persistent ability of the B-cell receptor in tumor cells from these cases to respond to antigen. As B-cell receptor signaling generally relies on T-cell help, we hypothesized that the course of B-CLL might not only be influenced by the Ig VH mutational status but also by the activation/differentiation status of T cells. We assessed the relative distribution of naive and memory T-cell subsets in peripheral blood from patients with mutated (M-CLL, n=71) and unmutated Ig VH genes (UM-CLL, n=42) and correlated it with the course of disease. We also compared the prosurvival potential of naive and memory T cells cocultured with B-CLL cells in vitro. A significant increase in relative numbers of central and effector memory T cells was observed in the CD4 T-cell pool from UM-CLL as compared with M-CLL cases and was associated with high Rai stage, progressive disease and shorter treatment-free survival (TFS). In a multivariate analysis, the relative number of CD4 central and effector memory T cells remained a significant prognostic parameter for TFS after correction for CD38 expression, Ig VH status, genomic aberrations, and Rai stage. The inverse correlation of memory CD4 T cells with TFS might be explained by their potential to support survival of B-CLL cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19242370     DOI: 10.1097/CJI.0b013e318197b5e4

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  13 in total

1.  B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion.

Authors:  Daniela Asslaber; Yuan Qi; Nicole Maeding; Markus Steiner; Ursula Denk; Jan Philip Höpner; Tanja Nicole Hartmann; Nadja Zaborsky; Richard Greil; Alexander Egle
Journal:  Blood       Date:  2019-11-14       Impact factor: 22.113

2.  Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.

Authors:  Francesca M Rossi; Maria Ilaria Del Principe; Davide Rossi; Maria Irno Consalvo; Fabrizio Luciano; Antonella Zucchetto; Pietro Bulian; Riccardo Bomben; Michele Dal Bo; Marco Fangazio; Dania Benedetti; Massimo Degan; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2010-03-08       Impact factor: 5.531

3.  Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome.

Authors:  Francesca Toia; Simona Buccheri; Ampelio Anfosso; Francesco Moschella; Francesco Dieli; Serena Meraviglia; Adriana Cordova
Journal:  PLoS One       Date:  2016-02-25       Impact factor: 3.240

4.  TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.

Authors:  Kemal Catakovic; Franz Josef Gassner; Christoph Ratswohl; Nadja Zaborsky; Stefan Rebhandl; Maria Schubert; Markus Steiner; Julia Christine Gutjahr; Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil; Roland Geisberger
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

5.  Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.

Authors:  E M Grössinger; L Weiss; S Zierler; S Rebhandl; P W Krenn; E Hinterseer; J Schmölzer; D Asslaber; S Hainzl; D Neureiter; A Egle; J Piñón-Hofbauer; T N Hartmann; R Greil; H H Kerschbaum
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

Review 6.  Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.

Authors:  Veronika Mancikova; Michal Smida
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

Review 7.  Involvement of memory T-cells in the pathophysiology of chronic lymphocytic leukemia.

Authors:  Rodolfo Patussi Correia; Flávia Amoroso Matos E Silva; Nydia Strachman Bacal; Paulo Vidal Campregher; Nelson Hamerschlak; Gustavo P Amarante-Mendes
Journal:  Rev Bras Hematol Hemoter       Date:  2014

8.  CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model.

Authors:  T Kocher; D Asslaber; N Zaborsky; S Flenady; U Denk; P Reinthaler; M Ablinger; R Geisberger; J W Bauer; M Seiffert; T N Hartmann; R Greil; A Egle; J Piñón Hofbauer
Journal:  Leukemia       Date:  2015-11-02       Impact factor: 11.528

9.  Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.

Authors:  Joachim R Göthert; Roze Imsak; Michael Möllmann; Stefanie Kesper; Maria Göbel; Ulrich Dührsen; Arne Scholz; Ulrich Lücking; Matthias Baumann; Anke Unger; Carsten Schultz-Fademrecht; Bert Klebl; Jan Eickhoff; Axel Choidas; Jan Dürig
Journal:  Oncotarget       Date:  2018-05-29

10.  Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Authors:  Alexander Egle; Michael Steurer; Thomas Melchardt; Lukas Weiss; Franz Josef Gassner; Nadja Zaborsky; Roland Geisberger; Kemal Catakovic; Tanja Nicole Hartmann; Lisa Pleyer; Daniela Voskova; Josef Thaler; Alois Lang; Michael Girschikofsky; Andreas Petzer; Richard Greil
Journal:  Ann Hematol       Date:  2018-06-04       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.